Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
By P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, I. Jacobson, M. Washington, G. Germanidis, John F Flaherty, R. Schall and 5 more. The Lancet, 2013
1,671 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/22f529a5eec22392b34a311b7c07de78b112c5b1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- M. Pinzani
- Natascha Roehlen
- E. Crouchet
- T. Baumert
- S. Friedman
- Christian Trautwein
- Steven Dooley
- Asociacion Latinoamericana para el Estudio del Higado
In Hepatology
- S. Friedman
- M. Pinzani
- T. Baumert
- Natascha Roehlen
- E. Crouchet
- Christian Trautwein
- Steven Dooley
- Asociacion Latinoamericana para el Estudio del Higado
Citations in the corpus
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “HBV Prolonged treatment with antiviral therapy is associated with resolution of liver fibrosis and regression of liver cirrhosis [269–271].”
- Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives (2020, background): “However, approximately 15% of patient with chronic viral liver infection do not show any reversal in liver fibrosis despite sustained viral response [228,229].”
- TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019 (2019, background): “Reversibility of liver fibrosis is evident in patients after removal of the causative agent of damage/disease [133,255], e.”
- Hepatic fibrosis: Concept to treatment. (2015, methodology): “This focus on NASH reflects both the astonishing improvement in the specific therapies for viral hepatitis, combined with the growing appreciation of the magnitude of the obesity and fatty liver disease epidemics, which affects up to tenfold more individuals than HCV in the US and Europe.”
- Molecular Biology of Hepatitis B Virus Infection (2015, neutral): “Nucleoside analog therapy can also inhibit and sometimes reverse the progression of cirrhotic and fibrotic liver injury (Marcellin et al., 2013; Tana and Hoofnagle, 2013), which can be life threatening.”